UK markets closed
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • FTSE 250

    22,775.28
    +283.92 (+1.26%)
     
  • AIM

    1,262.60
    +9.91 (+0.79%)
     
  • GBP/EUR

    1.1495
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.3990
    +0.0098 (+0.70%)
     
  • BTC-GBP

    41,505.96
    -336.95 (-0.81%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • DOW

    34,777.76
    +229.23 (+0.66%)
     
  • CRUDE OIL

    64.82
    +0.11 (+0.17%)
     
  • GOLD FUTURES

    1,832.00
    +16.30 (+0.90%)
     
  • NIKKEI 225

    29,357.82
    +26.45 (+0.09%)
     
  • HANG SENG

    28,610.65
    -26.81 (-0.09%)
     
  • DAX

    15,399.65
    +202.91 (+1.34%)
     
  • CAC 40

    6,385.51
    +28.42 (+0.45%)
     

Vaccine Adjuvants Market Report 2021-2031

ReportLinker
·5-min read

Forecasts by Type (Pathogen, Adjuvant Emulsion, Particulate, Combination, Others), by Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), by Disease Type (Infectious Diseases, Cancer, Others), by End-user (Pediatric, Adults, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Vaccine Adjuvants Companies AND COVID-19 Recovery Scenarios

New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Vaccine Adjuvants Market Report 2021-2031" - https://www.reportlinker.com/p06061826/?utm_source=GNW


Major Companies to Ramp Up Vaccine Adjuvant Production in 2021
According to Visiongain analysis, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global vaccine adjuvants market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the vaccine adjuvants market. For instance, in May 2020; GlaxoSmithKline announced that it will expand production of vaccine adjuvants to 1 billion doses in 2021. Additionally, the company announced that the vaccine adjuvants would be supplied to partner’s of COVID-19 vaccine candidates. These factors are projected to boost vaccine adjuvants market growth over the forecast period from 2021 to 2031.
Rising Demand from Emerging Economies to Offer Lucrative Revenue Generation Avenues
For the companies operating in the global vaccine adjuvants market, there is an immense opportunity from emerging economies across the globe. In the emerging economies, vaccine manufacturers and respective governments are investing in enhancing production capacity, which is anticipated to reduce the amount of protein required per dose over the forecast period. In addition to the demand arising from the ageing population and rising birth rates, the economic growth across the emerging markets is another major factor that is driving demand for the vaccine adjuvants.

Discover how to stay ahead
Our 310+ page report provides 450+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Vaccine Adjuvants Market. See how to exploit the opportunities.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com
Forecasts to 2031 and other analyses reveal the commercial prospects
. In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
. You find original analyses, with business outlooks and developments.
. Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), PEST Analysis, SWOT Analysis, product profiles and commercial developments.
Discover sales predictions for the world market and sub-markets
Type
. Pathogen
. Adjuvant Emulsion
. Particulate
. Combination
. Others
Route of Administration
. Intramuscular
. Subcutaneous
. Intradermal
. Others
Disease Type
. Infectious Diseases
. Cancer
. Others
End-User
. Pediatric
. Adults
. Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 14 leading national markets:
By Region
. North America
- U.S.
- Canada
. Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
. Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
. Latin America
- Brazil
- Mexico
- Rest of Latin America
. Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa

Leading companies and the potential for market growth
Overall world revenue for Vaccine Adjuvants Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Vaccine Adjuvants Market report helps you

In summary, our 310+ page report provides you with the following knowledge:
. Revenue forecasts to 2031 for Vaccine Adjuvants Market, with forecasts for Type, Route of Administration, Disease Type, and End-User, each forecasted at a global and regional level- discover the industry’s prospects, finding the most lucrative places for investments and revenues
. Revenue forecasts to 2031 for 5 regional and 14 key national markets- See forecasts for the Vaccine Adjuvants market in North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, China, India, Japan, GCC, and South Africa among other prominent economies.
. Prospects for established firms and those seeking to enter the market- including company profiles for 13 of the major companies involved in the Vaccine Adjuvants Market. Some of the company’s profiled in this report GSK, CSL, Agenus, Adjuvance, Novavax, SPI Pharma, Invivogen, Avanti Polar Lipids, Seppic, Croda, MVP Laboratories, OZ Biosciences, and Dynavax.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our new report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Vaccine Adjuvants Market and leading companies. You will find data, trends, and predictions.
Read the full report: https://www.reportlinker.com/p06061826/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001